{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T19:08:51Z","timestamp":1769886531694,"version":"3.49.0"},"reference-count":34,"publisher":"Japanese Society for Magnetic Resonance in Medicine","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["MRMS","magn reson med sci"],"published-print":{"date-parts":[[2026]]},"DOI":"10.2463\/mrms.mp.2025-0071","type":"journal-article","created":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T22:08:44Z","timestamp":1759442924000},"page":"n\/a","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of MR Imaging of High-grade Serous Carcinomas with and without Homologous Recombination-deficiency"],"prefix":"10.2463","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4530-7375","authenticated-orcid":false,"given":"Tsukasa","family":"Saida","sequence":"first","affiliation":[{"name":"Department of Radiology, Institute of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5633-1816","authenticated-orcid":false,"given":"Ayumi","family":"Shikama","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Institute of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9532-5411","authenticated-orcid":false,"given":"Miki","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Diagnostic and Interventional Radiology, University of Tsukuba Hospital, Tsukuba, Ibaraki, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7321-980X","authenticated-orcid":false,"given":"Taishi","family":"Amano","sequence":"additional","affiliation":[{"name":"Department of Radiology, Institute of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5018-4248","authenticated-orcid":false,"given":"Toshitaka","family":"Ishiguro","sequence":"additional","affiliation":[{"name":"Department of Radiology, Institute of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5048-992X","authenticated-orcid":false,"given":"Masafumi","family":"Sakai","sequence":"additional","affiliation":[{"name":"Department of Radiology, Institute of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3558-0258","authenticated-orcid":false,"given":"Sodai","family":"Hoshiai","sequence":"additional","affiliation":[{"name":"Department of Radiology, Institute of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6929-5463","authenticated-orcid":false,"given":"Toyomi","family":"Satoh","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Institute of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6704-2297","authenticated-orcid":false,"given":"Takahito","family":"Nakajima","sequence":"additional","affiliation":[{"name":"Department of Radiology, Institute of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1295","reference":[{"key":"1","unstructured":"1. World Cancer Research Fund International. Ovarian cancer statistics. https:\/\/www.wcrf.org\/preventing-cancer\/cancer-statistics\/ovarian-cancer-statistics (Accessed: July 11, 2025)"},{"key":"2","unstructured":"2. Soslow RA, Kong CS, Brenton JD, et al. Tumours of the ovary: High-grade serous carcinoma of the ovary. In: WHO Classification of Tumours Editorial Board, ed. WHO classification of tumours, 5th ed., Vol.4: Female genital tumours. Lyon:IARC Press, 2020; 45\u201347."},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Soslow RA, Han G, Park KJ, et al. Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma. Mod Pathol 2012; 25:625\u2013636.","DOI":"10.1038\/modpathol.2011.183"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Miller RE, Leary A, Scott CL, et al. ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer. Ann Oncol 2020; 31:1606\u20131622.","DOI":"10.1016\/j.annonc.2020.08.2102"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Ray-Coquard I, Pautier P, Pignata S, et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med 2019; 381:2416\u20132428.","DOI":"10.1056\/NEJMoa1911361"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474:609\u2013615.","DOI":"10.1038\/nature10166"},{"key":"7","unstructured":"7. MyChoice\u00ae CDx HRD Companion Diagnostic Test. https:\/\/myriad.com\/genetic-tests\/mychoicecdx-tumor-test\/ (Accessed: Jun. 14, 2025)"},{"key":"8","unstructured":"8. FoundationOne\u00aeCDx. https:\/\/www.foundationmedicine.com\/test\/foundationone-cdx (Accessed: Jun. 14, 2025)"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res 2014; 20:764\u2013775.","DOI":"10.1158\/1078-0432.CCR-13-2287"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Hennessy BTJ, Timms KM, Carey MS, et al. Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. J Clin Oncol 2010; 28:3570\u20133576.","DOI":"10.1200\/JCO.2009.27.2997"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Frey MK, Pothuri B. Homologous recombination deficiency (HRD) testing in ovarian cancer clinical practice: A review of the literature. Gynecol Oncol Res Pract 2017; 4:4.","DOI":"10.1186\/s40661-017-0039-8"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Stover EH, Fuh K, Konstantinopoulos PA, Matulonis UA, Liu JF. Clinical assays for assessment of homologous recombination DNA repair deficiency. Gynecol Oncol 2020; 159:887\u2013898.","DOI":"10.1016\/j.ygyno.2020.09.029"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Cao Y, Lu Y, Shao W, et al. Time-dependent diffusion MRI-based microstructural mapping for differentiating high-grade serous ovarian cancer from serous borderline ovarian tumor. Eur J Radiol 2024; 178:111622.","DOI":"10.1016\/j.ejrad.2024.111622"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Kawaguchi M, Kato H, Furui T, et al. Prediction of grading of ovarian endometrioid carcinoma using conventional MRI features. Jpn J Radiol 2025; 43:820\u2013828.","DOI":"10.1007\/s11604-024-01727-9"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Ohya A, Fujinaga Y. Magnetic resonance imaging findings of cystic ovarian tumors: Major differential diagnoses in five types frequently encountered in daily clinical practice. Jpn J Radiol 2022; 40:1213\u20131234.","DOI":"10.1007\/s11604-022-01321-x"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Saida T, Shikama A, Mori K, et al. Comparing characteristics of pelvic high-grade serous carcinomas with and without breast cancer gene variants on MR imaging. Magn Reson Med Sci 2024; 23:18\u201326.","DOI":"10.2463\/mrms.mp.2022-0061"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Vargas HA, Micc\u00f2 M, Hong SI, et al. Association between morphologic CT imaging traits and prognostically relevant gene signatures in women with high-grade serous ovarian cancer: A hypothesis-generating study. Radiology 2015; 274:742\u2013751.","DOI":"10.1148\/radiol.14141477"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Nougaret S, Lakhman Y, G\u00f6nen M, et al. High-grade serous ovarian cancer: Associations between BRCA mutation status, CT imaging phenotypes, and clinical outcomes. Radiology 2017; 285:472\u2013481.","DOI":"10.1148\/radiol.2017161697"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Li H, Lu J, Deng L, et al. Diffusion-weighted magnetic resonance imaging and morphological characteristics evaluation for outcome prediction of primary debulking surgery for advanced high-grade serous ovarian carcinoma. J Magn Reson Imaging 2023; 57:1340\u20131349.","DOI":"10.1002\/jmri.28418"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Suidan RS, Ramirez PT, Sarasohn DM, et al. A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer. Gynecol Oncol 2014; 134:455\u2013461.","DOI":"10.1016\/j.ygyno.2014.07.002"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Ledermann JA. PARP inhibitors in ovarian cancer. Ann Oncol 2016; 27(Suppl 1):i40\u2013i44.","DOI":"10.1093\/annonc\/mdw094"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Doig KD, Fellowes AP, Fox SB. Homologous recombination repair deficiency: An overview for pathologists. Mod Pathol 2023; 36:100049.","DOI":"10.1016\/j.modpat.2022.100049"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Meier A, Veeraraghavan H, Nougaret S, et al. Association between CT-texture-derived tumor heterogeneity, outcomes, and BRCA mutation status in patients with high-grade serous ovarian cancer. Abdom Radiol (NY) 2019; 44:2040\u20132047.","DOI":"10.1007\/s00261-018-1840-5"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Sims TT, Sood AK, Westin SN, et al. Correlation of HRD status with clinical and survival outcomes in patients with advanced-stage ovarian cancer. J Clin Oncol 2021; 39(15_suppl):5568.","DOI":"10.1200\/JCO.2021.39.15_suppl.5568"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Petrillo M, Marchetti C, De Leo R, et al. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: A multicenter study. Am J Obstet Gynecol 2017; 217:334.e1\u2013334.e9.","DOI":"10.1016\/j.ajog.2017.05.036"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Kekeeva T, Dudina I, Andreeva Y, et al. Molecular subgroups of HRD positive ovarian cancer and their prognostic significance. Int J Mol Sci 2024; 25:13549.","DOI":"10.3390\/ijms252413549"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Kim SR, Malcolmson J, Li X, Bernardini MQ, Hogen L, May T. The correlation between BRCA status and surgical cytoreduction in high-grade serous ovarian carcinoma. Gynecol Oncol 2021; 162:702\u2013706.","DOI":"10.1016\/j.ygyno.2021.07.010"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Howitt BE, Hanamornroongruang S, Lin DI, et al. Evidence for a dualistic model of high-grade serous carcinoma: BRCA mutation status, histology, and tubal intraepithelial carcinoma. Am J Surg Pathol 2015; 39:287\u2013293.","DOI":"10.1097\/PAS.0000000000000369"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Ritterhouse LL, Nowak JA, Strickland KC, et al. Morphologic correlates of molecular alterations in extrauterine M\u00fcllerian carcinomas. Mod Pathol 2016; 29:893\u2013903.","DOI":"10.1038\/modpathol.2016.82"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. D\u2019Angelo E, Espinosa I, Felicioni L, Buttitta F, Prat J. Ovarian high-grade serous carcinoma with transitional-like (SET) morphology: A homologous recombination-deficient tumor. Hum Pathol 2023; 141:15\u201321.","DOI":"10.1016\/j.humpath.2023.08.010"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Kime A, Bataillon G, Treilleux I, et al. Can morphology and immune infiltration predict the homologous recombination deficiency status in newly diagnosed high-grade serous ovarian carcinoma?: Lessons from the PAOLA-1\/ENGOT-ov25 Trial, a GINECO Study. Arch Pathol Lab Med 2025; 149:741\u2013750.","DOI":"10.5858\/arpa.2024-0081-OA"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Castro E, Goh C, Olmos D, et al. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol 2013; 31:1748\u20131757.","DOI":"10.1200\/JCO.2012.43.1882"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Wang YA, Jian J-W, Hung C-F, et al. Germline breast cancer susceptibility gene mutations and breast cancer outcomes. BMC Cancer 2018; 18:315.","DOI":"10.1186\/s12885-018-4229-5"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Hindman N, Kang S, Fournier L, et al. MRI evaluation of uterine masses for risk of leiomyosarcoma: A consensus statement. Radiology 2023; 306:e211658.","DOI":"10.1148\/radiol.211658"}],"container-title":["Magnetic Resonance in Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/mrms\/25\/1\/25_mp.2025-0071\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T03:57:45Z","timestamp":1769831865000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/mrms\/25\/1\/25_mp.2025-0071\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2463\/mrms.mp.2025-0071","relation":{},"ISSN":["1347-3182","1880-2206"],"issn-type":[{"value":"1347-3182","type":"print"},{"value":"1880-2206","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"mp.2025-0071"}}